Hopital De Libramont

Libramont-Chevigny 29 trials 9 recruiting

29 Registered trials

9 Currently recruiting

Organisation

Hopital De Libramont

Location

Libramont-Chevigny, Belgium

Identifier

ORG-100042301

Address

Avenue De Houffalize 35, 6800, Belgium

Departments

#1001: Oncologie
0502:Oncologie
Department of Oncology
Gastroenterology
Medical Oncology
Oncologie
Oncology

Clinical trials at this site (29)

Search interface

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 gastroesophageal junction adenocarcinoma 9 2024-08-05
Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting

2022-501220-14-00 epithelial ovarian, primary peritoneal, or fallopian tu 4 2023-10-17
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 locally advanced rectal cancer 5 2024-02-07
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To… Recruiting

2022-502357-34-00 Extensive Stage Small Cell Lung Cancer 5 2023-09-27
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended

2023-506842-22-00 Recurrent endometrial cancer, recurrent epithelial ovar 7 2025-05-19
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended

2024-511023-34-00 HER2-neg/low metastatic breast cancer 10 2023-05-05
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended

2024-514723-42-00 Locally advanced unresectable or metastatic, microsatel 9 2022-05-05
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 4 2021-08-05
DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended

2023-509865-19-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2021-04-30
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended

2022-502746-27-00 Endometrial Cancer 5 2020-08-21
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g… Ended

2023-504974-40-00 Estrogen Receptor Positive HER2 Negative Advanced Breas 4 2020-04-24
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended

2023-505796-76-00 Locally Advanced Squamous Cell Carcinoma of the Head an 3 2024-01-18
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Metastatic Colorectal Cancer (mCRC) 4 2023-06-02